| Document |
Document Title |
|
JP4615998B2 |
The invention relates to novel 9 alpha -substituted estratrienes of general formula (I) - wherein R3, R7, R7', R13, R16, R17 and R17' have the designations cited in the description, and R9 represents a linear-chain or branched-chain, opt...
|
|
JP4601936B2 |
The object of the present invention is to provide the use of glycyrrhizin and its derivatives for inhibition of MCP-1 production. The present invention discloses an MCP-1 production inhibition method and pharmaceutical composition for th...
|
|
JP4593864B2 |
The invention provides a continuous process for obtaining triterpenes from plants and/or their components. The process can include continuously washing at least one of plant and plant parts in counter-current at 20° C. to 70° C. with a...
|
|
JP4587647B2 |
|
|
JP4583511B2 |
The present invention is directed to novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carbo...
|
|
JP4553586B2 |
There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R<1> is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhi...
|
|
JP4541548B2 |
The present invention relates to a compound having formula: wherein (a) either A or B is a double bond such that when A is a double bond, C 11 has substituted thereon =X, and when B is a double bond, C 12 has substituted thereon =X, X be...
|
|
JP2010174031A |
To provide a new adjuvant relating fields of an adjuvant and an immunostimulator.There is provided a compound in which a lipophilic moiety such as a lipid, a fatty acid, polyethylene glycol or a terpene is covalently bound with a non-acy...
|
|
JP4517249B2 |
A substance excelling in the efficacy of melanogenesis promotion and being effective in hair graying prevention and amelioration and in skin melanism; and a composition making effective use of the substance. In particular, such a substan...
|
|
JP4497566B2 |
|
|
JP2010519219A |
This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regula...
|
|
JP4463621B2 |
|
|
JP2010095459A |
To provide a fat accumulation- or metabolism-ameliorating agent and an anti-TNF- agent obtained from the flower of Punica granatum L. of a plant belonging to the family Punicaceae, a drug or a food for humans or animals having a fat accu...
|
|
JP4442116B2 |
|
|
JP4437923B2 |
A process for a preparation of Compound (V), a pharmaceutically acceptable salt or a solvate thereof, said process comprising the steps represented by the following formula: wherein R<1> and R<2> are each independently C1 - C8 alkyl
|
|
JP2010504921A |
The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is der...
|
|
JP2010018552A |
To provide a renin inhibitor that can be continued for a long period of time by purifying a resin inhibitor that brings about a hypotensive effect by inhibiting renin being one vasopressor principle and is derived from a food having a sl...
|
|
JP4398147B2 |
The present invention relates to a food or beverage comprising at least one member selected from the group consisting of 5-membered ring-containing triterpenes and physiologically acceptable salts or derivatives thereof. The present inve...
|
|
JP4395551B2 |
|
|
JP4390177B2 |
|
|
JP2009292797A |
To provide an excellent therapeutic agent without causing deterioration of bladder shrinking force as adverse effects on the overactive bladder frequently caused by BOO (bladder outlet obstruction) such as prostatic hypertrophy wherein a...
|
|
JP4385243B2 |
|
|
JP2009539811A |
The invention relates to compounds derived from betulin, and to the use thereof in plant pest control, particularly as antifeedants for butterfly larvae, beetles and snails. Further, the invention relates to novel betulin derivatives and...
|
|
JP2009215317A |
To provide a sulfatase inhibitor which needs a compound limiting or preventing the usage of estrogen in hormone-dependent tumor, and does not have an estrogenic active component.The invention relates to a new estratriene expressed by gen...
|
|
JP2009530405A |
The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast ...
|
|
JP2009529572A |
The present invention relates to novel derivatives of 18beta-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivati...
|
|
JP4317278B2 |
|
|
JP2009527563A |
Substituted taraxastanes useful for treating viral infections, are provided herein. Thus, in a first aspect, the invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, wherein the variables R1, R2, a...
|
|
JP4301940B2 |
Antiobesity drugs containing, as the active ingredient, one or more members selected from among maslinic acid, erythrodiol, ursolic acid, uvaol, betulinic acid, betulin, physiologically acceptable salts thereof and derivatives of the sam...
|
|
JP2009523135A |
The present invention discloses a kind of Shinyleaf yellowhom extract mainly consisting of Shinyleaf yellowhom total saponins, which accounts for more than 5 0% of the total weight of the dried Shinyleaf yellowhom extract. The present in...
|
|
JP2009522239A |
The invention relates to triterpenequinone and triterpenephenol derivatives, their pharmaceutically acceptable 5 salts, prodrugs, solvates or stereoisomers as selective blocking agents of the choline kinase enzyme, pharmaceutical composi...
|
|
JPWO2007072845A1 |
Equation (I):(In the formula, R1Represents a hydrogen or metabolic ester residue, R2Is hydrogen or -R3-R4(Here R3Is -SO3-, -CH2COO-, -COCOO- or -COR5COO-(here R5Represents lower alkylene or lower alkenylene), R4Bleeding due to thrombecto...
|
|
JP2009518347A |
The present patent application relates to 11beta-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: wherein R1 is a hydrogen atom or a C1-C6-alkyl, C1-C6-acyl, C1-C4-alkoxycarbonyl, C1-C4-alkylthiocarbonyl, C1-C6-alky...
|
|
JP2009062322A |
To provide a hepatocyte regeneration promotor having a higher hepatocyte regeneration-promoting effect than those of conventionally used glycyrrhizin and its derivatives, and containing a glycyrrhetinic acid derivative as an active ingre...
|
|
JP2008546669A |
The invention provides for compounds having formula (1) wherein; R1 is O, (H,H), (H,OH), or NOR, with R being hydrogen, (C1-6) alkyl or (C1-6) acyl; R2 is hydrogen, methyl, ethyl, or ethenyl; R3 is hydrogen, methyl, ethyl, ethenyl, fluor...
|
|
JP2008540657A |
The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions...
|
|
JP2008273866A |
To provide a new anticancer agent containing a brassinosteroid derivative.This anticancer agent contains the brassinosteroid derivative which is a plant physiologically active material, as an active ingredient. The brassinosteroid does n...
|
|
JP4179795B2 |
|
|
JP2008255085A |
To provide a process for preparing high purity corosolic acid and high purity ursolic acid with a wide practical use field, from Japanese loquat leaves.The high purity corosolic acid and high purity ursolic acid are obtained by extractin...
|
|
JP2004517045A5 |
|
|
JP2008535923A |
The present invention relates to crystalline polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt (“DSB•2NMG)”), pharmaceutical compositions of the same and use of the same as an active pharmace...
|
|
JP2008528656A |
Triterpenic alkaloids (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. Triterpenic alkaloids of formula (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. R 1-CH 2X 1R 7, -CH=...
|
|
JP4106418B2 |
The present invention relates to a herbal drug composition for cartilage protection comprising plant extracts of Clematis Radix, Trichosanthis Radix, and Prunellae Spica and an optimal content of rosmarinic acid to: (i) alleviate pains; ...
|
|
JPWO2006077801A1 |
A method for producing a compound represented by the formula (II) by reacting the compound represented by the formula (I) with a hydrogen peroxide and a molybdenum catalyst.(In the formula, R1And R1’Are lower alkyls, each of which may ...
|
|
JP2008519857A |
The present invention relates to novel synthetic derivatives of betulin and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or a pharmaceutically acceptable salt or prodr...
|
|
JP2008120839A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP2008120840A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP2008105964A |
To provide a simple and low-cost manufacturing method for extracting, from a plant, saponin having industrially high versatility as a raw material from which components other than saponin are moderately removed.The manufacturing method o...
|
|
JP4057765B2 |
|
|
JP4052485B2 |
A composition and method of inhibiting tumor growth and treating malignant melanoma without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically app...
|
